Cargando…

Calcitonin Gene–Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison

Background: The previously approved botulinum toxin and nowadays promising calcitonin gene-related peptide (CGRP) monoclonal antibody have shown efficacy for preventing chronic migraine (CM). However, there is no direct evidence for their relative effectiveness and safety. In this study, we conducte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Jiajie, Zhang, Quanquan, Guo, Xiaoning, Liu, Wei, Xu, Chunyang, Hu, Xiaowei, Ni, Jianqiang, Lu, Haifeng, Zhao, Hongru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126691/ https://www.ncbi.nlm.nih.gov/pubmed/34012392 http://dx.doi.org/10.3389/fphar.2021.631204

Ejemplares similares

Calcitonin Gene-Related Peptide Monoclonal Antibodies Versus Botulinum Neurotoxin a in the Preventive Treatment of Chronic Migraine: An Adjusted Indirect Treatment Comparison Meta-Analysis
por: Chen, Yao-Yao, et al.
Publicado: (2021)

Temporal Patterns of Vertigo and Migraine in Vestibular Migraine
por: Yan, Manyun, et al.
Publicado: (2020)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
por: Scuteri, Damiana, et al.
Publicado: (2019)

Network Meta-Analysis of Calcitonin Gene-Related Peptide Receptor Antagonists for the Acute Treatment of Migraine
por: Xu, Fang, et al.
Publicado: (2019)

Botulinum Toxin Treatment for Limb Spasticity in Childhood Cerebral Palsy
por: Pavone, Vito, et al.
Publicado: (2016)

Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis
por: Wang, Xing, et al.
Publicado: (2021)

EHMTI-0037. Botulinum A toxin for treatment of chronic migraine
por: Grazzi, L, et al.
Publicado: (2014)

Tardive Dyskinesia After Aripiprazole Treatment That Improved With Tetrabenazine, Clozapine, and Botulinum Toxin
por: Aguilar, Lourdes, et al.
Publicado: (2019)

Botulinum Toxin A for the Treatment of a Child with SUNCT Syndrome
por: Zhang, Yi, et al.
Publicado: (2016)

Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study
por: Barrientos, Nelson, et al.
Publicado: (2003)

Botulinum Toxin—A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches
por: Kępczyńska, Katarzyna, et al.
Publicado: (2022)

Impact of delaying botulinum toxin treatment in patients with migraine during the COVID-19 pandemic
por: Nascimento, Henrique, et al.
Publicado: (2023)

Calcitonin gene-related peptide antagonists versus botulinum toxin A for the preventive treatment of chronic migraine protocol of a systematic review and network meta-analysis: A protocol for systematic review
por: She, Tianwei, et al.
Publicado: (2020)

Botulinum Toxin in the Treatment of Headache
por: Becker, Werner J.
Publicado: (2020)

Treatment of Depression with Botulinum Toxin
por: Wollmer, Marc Axel, et al.
Publicado: (2022)

Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention
por: Morgan, Kelsey Woods, et al.
Publicado: (2021)

Hull prospective analysis of Botulinum Toxin type A (Botox) use in the treatment of chronic migraine
por: Ahmed, F, et al.
Publicado: (2013)

Acupuncture and botulinum toxin A injection in the treatment of chronic migraine: A randomized controlled study
por: Naderinabi, Bahram, et al.
Publicado: (2017)

Erenumab: A novel calcitonin gene-related peptide receptor antagonist developed specifically for migraine prevention
por: Garg, Shuchita, et al.
Publicado: (2020)

There is Value in Anecdotal Reports of Relief from Migraine with Botulinum Toxin
por: Winett, Bill
Publicado: (2009)

Monoclonal Antibodies Against the Calcitonin Gene-Related Peptide and Its Receptor in Japanese Adolescents With Migraines
por: Katsuki, Masahito, et al.
Publicado: (2023)

Injecting botulinum toxin into the treatment of blepharospasm
por: Popescu, Marius Nicolae, et al.
Publicado: (2018)

Botulinum Toxin for the Treatment of Hand Tremor
por: Niemann, Nicki, et al.
Publicado: (2018)

Botulinum Toxin for the Treatment of Neuropathic Pain
por: Park, JungHyun, et al.
Publicado: (2017)

Botulinum toxin for treatment of restrictive strabismus()
por: Merino, Pilar S., et al.
Publicado: (2017)

Immunogenicity Associated with Botulinum Toxin Treatment
por: Bellows, Steven, et al.
Publicado: (2019)

Causes of Botulinum Toxin Treatment Failure
por: Shtefan, Valentina, et al.
Publicado: (2022)

Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins
por: Schaefer, Sara M., et al.
Publicado: (2015)

Hengli(®) Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
por: Liao, Limin, et al.
Publicado: (2022)

Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis
por: Wang, Xing, et al.
Publicado: (2022)

Botulinum Toxin Type A Therapy in Migraine: Preclinical and Clinical Trials
por: Shao, Yu-Feng, et al.
Publicado: (2013)

Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine
por: Herd, Clare P, et al.
Publicado: (2019)

Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale
por: Cohen, Fred, et al.
Publicado: (2022)

O059. Predictors of response to botulinum toxin for the treatment of chronic migraine: data from a Headache Center
por: Ornello, Raffaele, et al.
Publicado: (2015)

Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment
por: MaassenVanDenBrink, Antoinette, et al.
Publicado: (2018)

The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis
por: Fernández-Bravo-Rodrigo, Jaime, et al.
Publicado: (2022)

Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study
por: Varnado, Oralee J, et al.
Publicado: (2022)

Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis
por: Deng, Hong, et al.
Publicado: (2020)

Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine
por: Pederson, Susan, et al.
Publicado: (2021)

Treatment of Palatal Myoclonus with Botulinum Toxin Injection
por: Anis, Mursalin M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ru6l1lgustd8imq1otpeirn38a